Other safety alerts
|
| |
| The United Kingdom: Class 4 Medicines Defect Notification: Brilique 90mg Tablets |
| |
Medicines and Healthcare products Regulatory Agency (MHRA) announces that G Pharma Ltd has informed the MHRA that there is an error in the spelling of the active ingredient included on the imported carton of Brilique 90mg Tablets (ticagrelor) (batch number: 200507 (OMB VHVK), 200942 (OMB VHXF), 201136 (OMB VHXF)) The spelling should be ‘Ticagrelor’ but has been printed as ‘Tricagelor’ under the brand name and in the content statement.
Ticagrelor is used for the prevention of thromboembolism in patients with acute coronary syndromes or a history of myocardial infarction.
Healthcare professionals are to be aware of the incorrect spelling of the active ingredient on the carton when prescribing and or dispensing the product. When products from the affected batches are supplied or dispensed, please ensure that patients are aware of the spelling mistake on the carton. The correct spelling of the active ingredient is included in the patient information leaflet and printed on the blister foil within the packs.
Please refer to the following website in MHRA for details:
http://www.gov.uk/drug-device-alerts/class-4-medicines-defect-notification-brilique-90mg-tablets-el-25-a-slash-18
In Hong Kong, the above product is not a registered pharmaceutical product.
Ends/Friday, Apr 25, 2025
Issued at HKT 17:15
|
| |
